Investigating how chaperones affect TDP-43 in ALS
Exploring chaperone code control of TDP-43 function in ALS
This study is looking at how a helper protein called Hsp70 affects another protein linked to ALS, to find new ways to treat the disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Charlotte NIH-funded |
| Lab location | 1 site (Charlotte, United States) |
| Project ID | NIH-10724923 on NIH RePORTER |
What this research studies
This research explores the role of the Hsp70 molecular chaperone in the aggregation of TDP-43, a protein linked to amyotrophic lateral sclerosis (ALS). By examining how post-translational modifications of Hsp70 influence TDP-43's function and toxicity, the study aims to uncover potential therapeutic strategies for ALS. The researchers will utilize advanced techniques such as cross-linking mass spectrometry to analyze the interactions between Hsp70 and TDP-43 in both mammalian and yeast cells. This work could lead to a better understanding of the molecular mechanisms underlying ALS and identify new targets for treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with amyotrophic lateral sclerosis (ALS) or related neurodegenerative disorders.
Not a fit: Patients with other unrelated neurodegenerative diseases or those without TDP-43 aggregation issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel therapies that mitigate the effects of ALS by targeting TDP-43 aggregation.
How similar studies have performed: While the specific approach of this research is novel, previous studies have shown promise in targeting protein aggregation in neurodegenerative diseases.
Where this research is happening
Charlotte, United States
- University of North Carolina Charlotte — Charlotte, United States (Active)
Researchers
- Principal investigator: Truman, Andrew William — University of North Carolina Charlotte
- Study coordinator: Truman, Andrew William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.